Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Entera Bio Ltd. - Ordinary Shares (NQ:ENTX)

3.920 +1.870 (+91.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Entera Bio Ltd. - Ordinary Shares

< Previous 1 2 3 Next >
Which stocks are moving on Monday? ↗
Via Chartmill
Curious about the most active stocks on Monday? ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers Entera Bio (NASDAQ:ENTX) stock moved upwards by 86.6% to $3.83 during Monday's regular session. The company's market cap stands at $100.9 million. Gossamer Bio (NASDAQ:GOSS) shares moved... 
Via Benzinga
Monday's session: top gainers and losers ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
From Entera Bio Ltd.
Via GlobeNewswire
What's going on in today's after hours session ↗
Via Chartmill
Top movers analysis one hour before the close of the markets on 2026-06-22: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
From Entera Bio Ltd.
Via GlobeNewswire
Get insights into the top gainers and losers of Friday's after-hours session. ↗
Via Chartmill
News headline image
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
ENTX Rallies As Insiders Buy Company Shares — Retail Hopes For ‘Exciting Days’ Ahead ↗
Entera Bio said that the company chairman Geno J. Germano bought shares, in addition to directors Steven D. Rubin, Haya Taitel, and Sean Ellis. 
Via Stocktwits
Big Pharma Just Put Peptides Back on the Map – Which Players Are Still Under the Radar?
Via AB Newswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
Could Oral Osteoporosis Treatment Become the Next GLP-1-Style Blockbuster?
Via AB Newswire
News headline image
Market Brief: After Viking Therapeutics’ Results, Is Entera Bio the Oral Platform Play to Watch? (NASDAQ: ENTX)
Via AB Newswire
News headline image
Entera Bio Beats Q2 EPS Estimates ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
ENTX Stock Earnings: Entera Bio Meets EPS for Q2 2024 ↗
ENTX stock results show that Entera Bio met analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
3 Meme Stocks to Buy and Hold for Potential 300% Returns in 3 Years ↗
These are the meme stocks to buy as they represent fundamentally strong ideas with major growth acceleration catalysts. 
Via InvestorPlace
News headline image
3 Meme Stocks That Can Surge by 200% Before 2025 ↗
Don't wait too long on these attractive meme stocks to buy for 200% upside, as they represent good businesses with growth catalysts. 
Via InvestorPlace
News headline image
3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns ↗
These are the clinical-stage biotech stocks to buy, as they represent companies with an attractive product pipeline. 
Via InvestorPlace
News headline image
3 Meme Stocks to Buy on the Dip: June 2024 ↗
Investors can't miss out on meme stocks to buy on the dip since these represent fundamentally sound ideas with growth acceleration catalysts 
Via InvestorPlace
News headline image
7 Penny Stocks to Turn $3 Into $1 Million Within 36 Months ↗
Wise investors consider penny stocks to buy which represent companies with vigorous fundamentals and a robust growth outlook. 
Via InvestorPlace
News headline image
Rag to Riches: 3 Penny Stocks That Could Make Early Investors Rich ↗
These are the penny stocks to buy, representing businesses with a promising growth outlook for the long term. 
Via InvestorPlace
News headline image
3 Penny Stocks to Turn $50,000 Into $1 Million: June 2024 ↗
These are undervalued penny stocks to buy as they represent companies with the likelihood of multi-fold growth in revenue. 
Via InvestorPlace
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.